Sun CY, Chen MX. Additional considerations on vonoprazan triple therapy for Helicobacter pylori eradication: Implementation challenges and clinical perspectives. World J Gastroenterol 2025; 31(46): 113528 [DOI: 10.3748/wjg.v31.i46.113528]
Corresponding Author of This Article
Ming-Xian Chen, MD, Professor, Department of Gastroenterology, Tongde Hospital of Zhejiang Province, No. 234 Gucui Road, Hangzhou 310012, Zhejiang Province, China. chenmingxian2005@126.com
Research Domain of This Article
Health Care Sciences & Services
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Dec 14, 2025; 31(46): 113528 Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.113528
Additional considerations on vonoprazan triple therapy for Helicobacter pylori eradication: Implementation challenges and clinical perspectives
Chu-Ying Sun, Ming-Xian Chen
Chu-Ying Sun, Integrative Medicine Clinical College of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University, Hangzhou 310012, Zhejiang Province, China
Ming-Xian Chen, Department of Gastroenterology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang Province, China
Author contributions: Sun CY wrote the original draft and made revisions; Chen MX contributed to reviewing and editing.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Xian Chen, MD, Professor, Department of Gastroenterology, Tongde Hospital of Zhejiang Province, No. 234 Gucui Road, Hangzhou 310012, Zhejiang Province, China. chenmingxian2005@126.com
Received: August 27, 2025 Revised: October 2, 2025 Accepted: November 4, 2025 Published online: December 14, 2025 Processing time: 104 Days and 19.1 Hours
Core Tip
Core Tip: Han et al’s multicenter trial demonstrates vonoprazan triple therapy’s superior efficacy over standard bismuth quadruple therapy for Helicobacter pylori eradication in China, successful nationwide implementation faces critical challenges. Key barriers include limited drug accessibility in primary healthcare settings, higher costs compared to traditional therapies, and significant regional variations in antibiotic resistance patterns across China’s diverse population. The study’s single-province design cannot fully represent national applicability. Addressing these implementation gaps through comprehensive health system research, cost-effectiveness analyses, and multi-regional validation studies is essential for translating these promising clinical findings into improved patient outcomes across China’s heterogeneous healthcare landscape.
